Featuring a slide presentation and related discussion from Dr L Elizabeth Budde, including the following topics:
- Overview of approved and investigational CD20 x CD3 bispecific antibodies (BsAbs) in non-Hodgkin lymphoma; key findings from Phase II studies evaluating glofitamab and epcoritamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (0:00)
- Bringing BsAbs into earlier-line settings; key findings from Phase III studies (7:49)
- Key findings from the Phase III EPCORE DLBCL-1 and EPCORE DLBCL-4 studies and Phase II EPCORE NHL-1 study (14:12)
- A Phase Ib/II study of glofitamab/polatuzumab in R/R large B-cell lymphoma; investigating the use of BsAbs as front-line therapy and as combination therapy (17:58)
- Managing treatment-related adverse events; final takeaways (22:53)